More specifically, with a sample size of 802 PSP cases and 1312 controls (the same control group examined in the current study), the MAPT H2 haplotype was more strongly associated with PSP (OR = 0.16, P = 7 × 10−49) than CBD (OR = 0.26, P = 2 × 10−12), H1d was significantly associated with an increased risk of PSP (OR = 1.86, P = 2 × 10−6) with a similar effect size compared to CBD (OR = 1.76, P = 0.002), while H1c was also more strongly associated with PSP risk (OR = 2.15, P = 2 × 10−14) than it was with CBD (OR = 1.49, P = 0.009). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.